ClinicalTrials.gg
RecruitingNCT07301567Updated Nov 18, 2026

Pilot Study of Negative Pressure Neck Therapy (NPNT)

An interventional study of Negative Pressure Neck Therapy (NPNT) in Obstructive Apnea, Sleep Apnea Syndrome, Obstructive and Sleep Disorder (Disorder), sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of British Columbia · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Sleep Apnea, Obstructive by University of British Columbia — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea, Obstructive · University of British Columbia.

Planned enrollment
12th of 14
10 · median 31
Started
2025
with 1 other
No phase
12 of 16
3 open now
Registered
16th of 16
by date

Among the 16 studies in Sleep Apnea, Obstructive by University of British Columbia, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 16th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

4 of the 16 studies in Sleep Apnea, Obstructive by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Apnea, Obstructive by University of British Columbia, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. This pilot study will evaluate the Safety and Efficacy of Negative Pressure Neck Therapy (NPNT) in up to 10 healthy participants. Participants will undergo 2 separate home sleep apnea tests (HSAT) approximately 1 week apart and will be randomly assigned to wear the NPNT device at either night 1 or night 2 of HSAT. Participation will include 5 on-site visits and 1 phone call over approximately 1 month.

Read the detailed description

Purpose: To determine the safety and efficacy of the Negative Pressure Neck Therapy (NPNT) in Healthy Participants.

Negative pressure neck therapy (NPNT) uses a self-contained, non-invasive, external device to apply a gentle, outward pulling effect around the neck's surface.

Hypothesis: Given the exploratory nature and small sample size no formal hypothesis testing will be conducted

Objectives:

Primary Objective:

1. To determine if NPNT can effectively reduce the number of apnea-hypopnea index (AHI) events (sleep disorder breathing events) in healthy participants.

Secondary Objectives:

  1. To determine the tolerability of the NPNT
  2. To determine the duration of time required for acclimating to the device
  3. To determine the NPNT parameters (optimal device fit) based on participant characteristics.
  4. To collect feedback from participants regarding the device use, comfort, fit, function, usability, etc.

Safety and Efficacy Objectives:

  1. To evaluate the safety and effectiveness of NPNT
  2. To assess potential side effects of NPNT.
03

Conditions studied

  • Obstructive Apnea
  • Sleep Apnea Syndrome, Obstructive
  • Sleep Disorder (Disorder)

Keywords

  • sleep apnea
  • Obstructive sleep apnea
  • sleep disordered breathing
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≤42 kg/m2
  • Able to speak, read, and write English

Exclusion criteria

Exclusion Criteria:

  • Known sleep disorder such as Obstructive Sleep Apnea (OSA), narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia
  • No previous surgery, injury, or radiation to the neck
  • Excessive hair or beard in the area of the neck, and/or unwillingness to shave that area for the duration of this study
  • Inflammatory skin condition, such as acne or eczema in the neck area
  • Known silicone allergy
  • Night shift work because of irregular sleep-wake cycles
  • Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks
  • Use of illicit drugs currently or within the past 5 years
  • Serious pulmonary disease
  • Use of home oxygen or oxygen saturation \<94%
  • Cancer that has been in remission for less than one year
  • Previous surgery for peripheral arterial disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Group 1

    One night of Home sleep apnea testing (HSAT) with Negative Pressure Neck Therapy (NPNT) intervention, followed by 7 night washout, then one night of HSAT only

    Device: Negative Pressure Neck Therapy (NPNT)

  • Experimental
    Group 2

    One night of HSAT only, followed by 7 night washout, then one night of HSAT with NPNT intervention.

    Device: Negative Pressure Neck Therapy (NPNT)

Interventions

  • DeviceNegative Pressure Neck Therapy (NPNT)

    Negative pressure neck therapy (NPNT) is a self-contained, non-invasive, soft, flexible, external neck collar

06

What researchers measure

Primary outcomes

  1. Comparison of the number of sleep-disordered breathing events between intervention and control nights as assessed by Home Sleep Apnea Test (HSAT).

    Change between control night and intervention night on mean AHI (Apnea-Hypopnea Index) scores. A positive treatment effect will be attributed to the NPNT device if the difference between the mean AHI score on intervention night is less than the mean AHI score on control night. A score of less than 0 is positive. Measurement Tool: HSAT (Home Sleep Apnea Test) Unit of Measure: AHI (Apnea-Hypopnea Index) scores

    Time frame: 1 night

Secondary outcomes

  1. Tolerability of NPNT device based on duration of time (hours) worn during NPNT intervention night as assessed by Participant Report and Home Sleep Apnea Test (HSAT)

    Wear time (hours) of NPNT device will be assessed for each participant during the NPNT intervention night, after 7 day NPNT acclimatization period. Mean, median, range of tolerability of scores will be reported. Measurement Tool: Participant Reported and HSAT (Home Sleep Apnea Test) Unit of Measure: hours

    Time frame: 1 night

  2. Participant Characteristics will be assessed compared to NPNT device fit/shape based on participant response on the Device Evaluation Questionnaire using Likert scores.

    Descriptive participant traits (age, BMI, craniofacial markers, etc.) will plotted against NPNT device fit/shape Likert scores from the Device Evaluation Questionnaire above and below a score of 3. For example, fit/shape Likert score rating by BMI category. Measurement Tool: Device Evaluation Questionnaire and Participant demographics Unit of Measure: Likert Score

    Time frame: 1 night

  3. Participant reported device tolerability will be assessed using the Device Evaluation Questionnaire Likert scale responses.

    Proportion of participants rating NPNT device as "tolerable" (≥3 on Likert scale) during NPNT intervention night, after 7 day acclimatization period. Measurement Tool: Device Evaluation Questionnaire Unit of Measure: Likert scale

    Time frame: 1 night

  4. Participant Reported Feedback on shape and fit of NPNT device as assessed by the Device Evaluation Questionnaire using a Likert Scale (≥3 on Likert scale)

    Proportion of participants rating device as "Moderate/good/excellent" (e.g., ≥3 on Likert scale). Mean, median, range of shape/fit scores, including a breakdown by demographic/ BMI group will be assessed after NPNT intervention night and 7 day acclimatation period. Measurement Tool: Device Evaluation Questionnaire Unit of Measure: Likert scale

    Time frame: 1 night

  5. Participant Feedback on NPNT device comfort, usability and function based on the Device Evaluation Questionnaire using a Likert scale

    Proportion of participants rating device comfort, usability and function as ≥3 on Likert scale. Mean, median, range of device comfort, usability and function scores, including a breakdown by demographic/ BMI group will be assessed after NPNT intervention night and after 7 day acclimatation period. Measurement Tool: Device Evaluation Questionnaire Unit of Measure: Likert scale

    Time frame: 1 night

  6. Participant Feedback on NPNT device based on qualitative data (open comments) from the Device Evaluation Questionnaire after the NPNT device intervention night.

    Qualitative data will be summarized using simple thematic coding based on participant open comment section of the Device Evaluation Questionnaire after the NPNT device intervention night, after 7 day acclimatization period. Measurement Tool: Device Evaluation Questionnaire Unit of Measure: Qualitative data (open comments)

    Time frame: 1 night

Other outcomes

  1. Adverse Events based on Device Evaluation Questionnaire responses to adverse device effects after NPNT intervention night and 7 night acclimatization period.

    Device specific adverse events (skin irritation, redness or rash, discomfort or pain, swelling, other) will be assessed using a scale of 1 to 5 (not at all, mild, moderate, severe, very severe) after the NPNT intervention night and 7 night acclimatization period. Measurement Tool: Device Evaluation Questionnaire Unit of Measure: Scale of 1-5 (1-not at all, 2-mild, 3-moderate, 4-severe, 5-very severe)

    Time frame: 8 nights

07

Study locations

1 of 2 sites recruiting
  • Centre for Lung Health
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
    • · Contact6048754122
  • Leon Judah Blackmore Centre for Sleep Disorders
    Vancouver, British Columbia V6T 2B5, Canada
    Not yet recruiting
    • · Contact6048754122
08

References and documents

Individual participant data

Plan to share: Undecided — This is a pilot study, so only IPD used in the results publication may be shared in the future.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Dec 2025, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 24, 2025
StartActual
Dec 16, 2025was Jan 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Centre for Lung Health · Vancouver, Canadano status→Recruiting
  • Leon Judah Blackmore Centre for Sleep Disorders · Vancouver, Canadano status→Not yet recruiting
Nov 18, 2026
Start date
Jan 2026→Dec 16, 2025 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Centre for Lung Health · Vancouver, Canadano status→Recruiting
    • Leon Judah Blackmore Centre for Sleep Disorders · Vancouver, Canadano status→Not yet recruiting
    Start date Jan 2026→Dec 16, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07301567
Collaborators
Vancouver Coastal Health Research Institute
Responsible party
John Fleetham (Professor, University of British Columbia) — Principal investigator
First posted
Dec 24, 2025
Start date
Dec 16, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Research Manager
Contact
Shelley.Abercromby@vch.ca
6048754111 ext. 62500
John A Fleetham, MD
principal investigator · VCHA/UBC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion